#recurrence — Thursday, February 26, 2026 (1 items)
| 0 | 💬 0 |
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
(nejm.org)
|
New England Journal of Medicine 2026-02-26 | #clinical trial #immunotherapy #breast cancer #her2 #recurrence |